Washington was supposed to lower drug prices in 2019. What happened?
Nearly everyone thought 2019 would be a big year for drug pricing. But neither Congress nor the White House enacted major policies to bring down costs.
Nearly everyone thought 2019 would be a big year for drug pricing. But neither Congress nor the White House enacted major policies to bring down costs.
From body bags for rapid cooling to “prescriptions” for air conditioners, doctors are preparing for a future of extreme heat linked to climate change.
New research ties hearing aids to slower cognitive decline in those at higher risk of dementia.
Pharmaceutical giant Johnson & Johnson is the third drugmaker to sue the Biden administration over its new Medicare drug price negotiation program.
“GPT-4, being trained off of our own textual communication, shows the same — or maybe even more exaggerated — racial and sex biases as humans”…
The new Pfizer partnership with Flagship will fund the development of up to 10 drug candidates.
Join STAT for a discussion of what’s next for biosimilars, and what key signals will indicate how they might be prescribed, or paid for.
“Increasingly, I think patients, health insurers, providers and even investors are really saying, ‘How do we make sure digital health tools work, and what does…
From body bags for rapid cooling to “prescriptions” for air conditioners, doctors are preparing for a future of extreme heat linked to climate change.